Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood

Lancet

Volumn 350, Issue 9071, 1997, Pages 91-95

  Kony, Sabine J ^a,e   De Vathaire, Florent ^b   Chompret, Agnès ^c   Shamsaldim, Akthar ^a,d   Grimaud, Emmanuel ^a,b   Raquin, Marie Anne ^c   Oberlin, Odile ^a   Brugières, Laurence ^c   Feunteun, Jean ^a   Eschwège, François ^a   Chavaudra, Jean ^b   Lemerle, Jean ^a   Bonaïti Pellié, Catherine ^a  

^a INSERM   (France)

^b Department of Paediatrics ^*  (France)

^c Physics Department   (France)

^d Laboratory of Oncological Genetics   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; HEREDITY; HUMAN; IONIZING RADIATION; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; PRIORITY JOURNAL; RADIATION DOSE; SECOND CANCER; TUMOR SUPPRESSOR GENE;

EID: 18744431219     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)01116-1     Document Type: Article

References (28)

1. Dorman JS, Trucco M, LaPorte RE, Kuller LH. Family studies: the key to understanding the genetic and environmental etiology of chronic disease? Genet Epidemiol 1988; 5: 305-11.
2. Friend SH, Bernards R, Rogeli S, et al. A human DNA segment with properties of a gene which highly predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-46.
3. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-38.
4. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1991; 249: 181-86.
5. Miki Y, Swensen J, Shattuck Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
6. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
7. Kitchin FD, Ellsworth RM. Pleiotropic effects of the gene for retinoblastoma. J Med Genet 1974; 11: 244-46.
8. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85: 1121-28.
9. Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA 1982; 247: 2692-94.
10. Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992; 326: 1309-15.
11. 1 Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl J Med 1986; 314: 1010-15.
12. Weber W. Cancer control by family history. Anticancer Res 1993; 13: 1197-202.
13. Tucker MA, Meadows AT, Boice JD Jr, Hoover RN, Fraumeni JF Jr: the late effects study group. Cancer risk following treatment of childhood cancer. In: Boice JD, Fraumeni JF, eds. Radiation carcinogenesis: epidemiology and biological significance. New York: Raven Press, 1984: 211-24.
14. Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the late effects study group. J Clin Oncol 1985; 3: 532-38.
15. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours amongst childhood cancer survivors. Br J Cancer 1987; 56: 339-47.
16. de Vathaire F, François P, Hill C, et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 1989; 59: 792-96.
17. Strong LC, Stine M, Nordsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 1987; 79: 1213-20.
18. Tucker A, D'Angio DJ, Boice JD, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588-96.
19. Hawkins MM, Kinnier Wilson LM, Burton HS, et al. Radiotherapy alkylating agent and the risk of bone cancer. J Natl Cancer Inst 1996; 88: 270-78.
20. Diallo I, Lamon A, Shamsaldin A, Grimaud E, de Vathaire F, Chavaudra J. Estimation of the radiation dose delivered at any point in the body for individual patient in external beam radiotherapy. Radiother Oncol 1996; 38: 269-78.
21. Schwartz AG, Boehnke M, Moll PP. Family risk index as a measure of familial heterogeneity of cancer risk: a population-based study in metropolitan Detroit. Am J Epidemiol 1988; 128: 524-35.
22. Malecot E. Les mathématiques de l'hérédité. Paris: Massen, 1948.
23. Kerber RA. Methods for calculating risk associated with family history of a disease. Genet Epidemiol 1995; 12: 291-301.
24. Parkins DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powel J. Cancer incidence in five continents, vol VI. Lyon: IARC, 1992.
25. Breslow NE, Day NE. Statistical methods in cancer: the analysis of case-control studies. Lyon: IARC, 1980.
26. Darroudi F, Vyas RC, Vermeulen S, Natarajan AT. G2 radio sensitivity of cells derived from cancer-prone individuals. Mutat Res 1995; 328: 83-90.
27. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia telangiectasia. J Natl Cancer Inst 1986; 77: 89-92.
28. Chakraborty R, Sankaranarayanan K. Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers, II: a mendelian single-locus model of cancer predisposition and radiosensitivity for predicting cancer risks in populations. Radiat Res 1995; 143: 293-301.